资讯

Investor's Business Daily on MSN15 分钟
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.
Stocktwits on MSN1 小时
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
Brokerage H.C. Wainwright on Wednesday opined that there will be” little intrinsic value” in Sarepta Therapeutics (SRPT) if ...
Fierce Pharma3 小时
FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys
In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...
STAT4 小时
Pharmalittle: We’re reading about FDA probing deaths after Sarepta treatment, a Regeneron ...
The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...
MedPage Today4 小时
FDA Probes Gene Therapy After Two Deaths
Duchenne muscular dystrophy is characterized by a mutation in the DMD gene that leads to a lack of dystrophin and muscle loss ...
pharmaphorum6 小时
FDA probing deaths with DMD gene therapy Elevidys
Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...
FDA investigates patient deaths after treatment with Sarepta's gene therapy
Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and ...